Diatron Introduces New Aquila 5Dretic 5-Part Differential Hematology Analyzer
|
By LabMedica International staff writers Posted on 20 Nov 2019 |

Image: Diatron Aquila 5Dretics (Photo courtesy of Diatron)
Diatron (Budapest, Hungary) introduced its new high throughput, 5-part differential hematology analyzer with continuous loading autoloader for the first time at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.
Diatron, a global provider of hematology and clinical chemistry analyzers, also showcased its P500 flagship clinical chemistry analyzer, and the Diatron KleeYa, an open, flexible CLIA platform, and demonstrated the Aquila 3-part diff hematology analyzer from its current hematology product portfolio.
The Diatron Aquila 5Dretics is the smallest and most compact cap piercing 5-part differential hematology analyzer with a maximum throughput of 80 tests per hour. It has a low reagent consumption (<30 ml), requires a small sample volume (40 ul) and has a continuous loading autoloader, making the walk away system convenient for all customers. It uses only two reagents as it is a fully optical system, resulting in low reagent consumption and making it more cost-effective. The Diatron Aquila 5Dretics requires little bench space (32 cm W x 30 cm D x 37 cm H without autoloader) and features a large touch screen, an intuitive user interface and a protected reagent pack system with unique connection
At the 2019 edition of MEDICA, Diatron also showcased its P500 flagship clinical chemistry analyzer. The P500 is an ergonomically designed, user-friendly system that offers a high level of automation and delivers assured result quality. The cost-effective, walkaway system is intended for medium throughput usage, providing results for 215 tests per hour on a typical sample mix. Also showcased at the event was Diatron KleeYa, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.
Additionally, Diatron demonstrated the Aquila 3-part diff hematology analyzer which offers a throughput of 60 tests per hour, requires a sample size of only 10µl, and consumes less than 10ml of reagent per test. It is equipped with an onboard reagent pack sufficient for approximately 200 measurements and includes a touchscreen, intuitive user interface, optional backup battery pack, and extended connectivity options.
Related Links:
Diatron
Diatron, a global provider of hematology and clinical chemistry analyzers, also showcased its P500 flagship clinical chemistry analyzer, and the Diatron KleeYa, an open, flexible CLIA platform, and demonstrated the Aquila 3-part diff hematology analyzer from its current hematology product portfolio.
The Diatron Aquila 5Dretics is the smallest and most compact cap piercing 5-part differential hematology analyzer with a maximum throughput of 80 tests per hour. It has a low reagent consumption (<30 ml), requires a small sample volume (40 ul) and has a continuous loading autoloader, making the walk away system convenient for all customers. It uses only two reagents as it is a fully optical system, resulting in low reagent consumption and making it more cost-effective. The Diatron Aquila 5Dretics requires little bench space (32 cm W x 30 cm D x 37 cm H without autoloader) and features a large touch screen, an intuitive user interface and a protected reagent pack system with unique connection
At the 2019 edition of MEDICA, Diatron also showcased its P500 flagship clinical chemistry analyzer. The P500 is an ergonomically designed, user-friendly system that offers a high level of automation and delivers assured result quality. The cost-effective, walkaway system is intended for medium throughput usage, providing results for 215 tests per hour on a typical sample mix. Also showcased at the event was Diatron KleeYa, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.
Additionally, Diatron demonstrated the Aquila 3-part diff hematology analyzer which offers a throughput of 60 tests per hour, requires a sample size of only 10µl, and consumes less than 10ml of reagent per test. It is equipped with an onboard reagent pack sufficient for approximately 200 measurements and includes a touchscreen, intuitive user interface, optional backup battery pack, and extended connectivity options.
Related Links:
Diatron
Latest Medica 2019 News
- Mast Group Introduces New MAST CARBA PAcE for Rapid Carbapenemase Detection
- DRG Instruments Demonstrates DRG:HYBRID-XL Fully Automated Lab Analyzer
- Alifax S.r.l. Highlights First Automated System for Bacterial Culture and Susceptibility Testing
- Erba Mannheim Showcases New Launches at MEDICA 2019
- EUROIMMUN Showcases Immunoassay Testing Products at MEDICA 2019
- Diconex S.A. Exhibits InCCA Intelligent Clinical Chemistry Analyzer at MEDICA 2019
- Chembio Diagnostics Showcases New DPP Line of Rapid Tests at MEDICA 2019
- DYNEX Demonstrates DYNABLOT Automatic Analyzer for Immunoblot and Westernblot Methods
- Systec Launches New and Improved HX-150 Autoclave at MEDICA 2019
- TaiDoc Showcases Multi-Parameter Monitoring Systems and Advanced Devices
- IDS Exhibits Next Generation Automated Immunoanalyzer IDS-i10 at MEDICA 2019
- JEOL Ltd. Introduces BioMajesty Series of Clinical Chemistry Analyzers at MEDICA 2019
- EKF Diagnostics Showcases Full Product Range at MEDICA 2019
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








